Induction of Interleukin 3 and Tumor Resistance by SSM, a Cancer Immunotherapeutic Agent Extracted from Mycobacterium tuberculosis

Keyphrases

• Mycobacterium Tuberculosis (M. tb) 100%
• Immunotherapeutics 100%
• Interleukin-3 100%
• Cancer Immunotherapeutics 100%
• Tumor Resistance 100%
• Monoclonal Antibody 50%
• Culture Liquid 41%
• T Cells 25%
• Tumor 25%
• Antiserum 25%
• Antitumor Activity 16%
• Nonhost Resistance 16%
• Interleukin-1β 8%
• Immunomodulator 8%
• Interferon-α (IFN-α) 8%
• In Vivo Growth 8%
• Interleukin-2 8%
• Serum Interleukins 8%
• Bacillus Calmette 8%
• Lymph Node Cells 8%
• Inguinal Lymph Node 8%
• IMC Growth 8%
• Intralesional Injection 8%
• Mouse Immunoglobulin 8%

Immunology and Microbiology

• Immunomodulating Drugs 100%
• Mycobacterium Tuberculosis 100%
• Interleukin 3 100%
• Liquid 50%
• Monoclonal Antibody 50%
• Mycobacterium Bovis BCG 41%
• T Cell 25%
• Antineoplastic Activity 16%
• Interleukin 1 8%
• Murine 8%
• Antiserum 8%
• Immunoglobulin Antibody 8%
• CD2F1 Mouse 8%
• Interleukin 2 8%
• Lymph Node Cell 8%
• Inguinal Lymph Node 8%
• Interferon Antibody 8%

Veterinary Science and Veterinary Medicine

• Mouse 100%
• T Cell 30%
• BALB/c 10%